Plain-English translation of NCT07444541 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Pancreatic Cancer research guide โPhase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new medication, combined with chemotherapy to treat pancreatic cancer that has spread or cannot be surgically removed. The study wants to see if this medication is safe and whether it helps patients live longer and feel better. Your pancreatic cancer must have specific markers (called CLDN18.2) that make it eligible for this trial.
Pancreatic cancer is a serious disease, and current treatments don't work well enough for everyone. Researchers believe that adding this new medication to standard chemotherapy might give patients better results and longer survival.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive the new medication () by injection alongside standard chemotherapy. You may be assigned to one of two treatment groups that differ in which chemotherapy drugs are paired with the medication. Throughout the trial, you will have regular clinic visits for blood tests, scans, and check-ups to monitor how the treatment is working and any side effects you might experience.
AI-generated summary from trial data ยท Nov 17, 2026 ยท Not medical advice
United States